2023 Q1 Form 10-K Financial Statement

#000095017023005113 Filed on February 28, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $5.678M $18.20M $131.8M
YoY Change 1291.67% 164.62% 1634.61%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.529M $7.939M $32.42M
YoY Change -2.85% 3.93% 24.37%
% of Gross Profit
Research & Development $31.83M $29.89M $119.1M
YoY Change 20.3% 6.86% 32.23%
% of Gross Profit
Depreciation & Amortization $441.0K $455.0K $1.978M
YoY Change -14.53% 23.64% 34.47%
% of Gross Profit
Operating Expenses $40.36M $37.83M $151.6M
YoY Change 14.54% 6.23% 30.42%
Operating Profit -$34.68M -$19.80M
YoY Change -0.42% -81.78%
Interest Expense $3.371M $2.989M $5.939M
YoY Change 2909.82% 5648.08% 5064.35%
% of Operating Profit
Other Income/Expense, Net $3.356M $13.00K $5.896M
YoY Change 3126.92% -165.0% 7867.57%
Pretax Income -$31.33M -$16.63M -$13.90M
YoY Change -9.79% -42.06% -87.2%
Income Tax $3.616M $15.03M $15.15M
% Of Pretax Income
Net Earnings -$34.94M -$31.66M -$29.05M
YoY Change 0.53% 11.91% -72.83%
Net Earnings / Revenue -615.38% -173.96% -22.03%
Basic Earnings Per Share -$0.83 -$0.69
Diluted Earnings Per Share -$0.83 -$0.75 -$0.69
COMMON SHARES
Basic Shares Outstanding 42.08M 41.96M 41.92M
Diluted Shares Outstanding 42.04M 41.92M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $314.1M $343.9M $343.9M
YoY Change 2.95% 2.84% 2.84%
Cash & Equivalents $121.5M $159.5M $159.5M
Short-Term Investments $192.7M $184.4M $184.4M
Other Short-Term Assets $4.389M $5.715M $5.715M
YoY Change 12.11% -9.49% -9.49%
Inventory
Prepaid Expenses $4.389M $5.715M
Receivables
Other Receivables $4.323M
Total Short-Term Assets $325.5M $354.0M $354.0M
YoY Change 1.97% 0.73% 0.73%
LONG-TERM ASSETS
Property, Plant & Equipment $5.396M $4.228M $9.599M
YoY Change -0.02% -24.55% -26.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $408.0K $497.0K $497.0K
YoY Change -30.38% -15.19% -88.18%
Total Long-Term Assets $10.78M $10.10M $10.10M
YoY Change -39.85% -41.64% -41.64%
TOTAL ASSETS
Total Short-Term Assets $325.5M $354.0M $354.0M
Total Long-Term Assets $10.78M $10.10M $10.10M
Total Assets $336.3M $364.1M $364.1M
YoY Change -0.25% -1.26% -1.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.620M $461.0K $461.0K
YoY Change 134.15% -79.97% -79.97%
Accrued Expenses $19.54M $23.55M $23.55M
YoY Change 5.82% 17.93% 17.93%
Deferred Revenue $52.76M $53.10M
YoY Change 344.33% 345.45%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $80.94M $78.62M $78.62M
YoY Change 137.46% 124.06% 124.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.127M $5.939M $5.939M
YoY Change -90.71% -86.86% -86.86%
Total Long-Term Liabilities $4.127M $5.939M $5.939M
YoY Change -90.71% -86.86% -86.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $80.94M $78.62M $78.62M
Total Long-Term Liabilities $4.127M $5.939M $5.939M
Total Liabilities $85.06M $84.56M $84.56M
YoY Change 8.37% 5.31% 5.31%
SHAREHOLDERS EQUITY
Retained Earnings -$274.3M -$239.3M
YoY Change 11.93% 13.81%
Common Stock $525.7M $519.3M
YoY Change 4.38% 4.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $251.2M $279.5M $279.5M
YoY Change
Total Liabilities & Shareholders Equity $336.3M $364.1M $364.1M
YoY Change -0.25% -1.26% -1.26%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$34.94M -$31.66M -$29.05M
YoY Change 0.53% 11.91% -72.83%
Depreciation, Depletion And Amortization $441.0K $455.0K $1.978M
YoY Change -14.53% 23.64% 34.47%
Cash From Operating Activities -$31.79M -$29.64M $322.0K
YoY Change 5.93% 42.91% -100.38%
INVESTING ACTIVITIES
Capital Expenditures $475.0K -$1.720M $602.0K
YoY Change -2.46% 942.42% -64.38%
Acquisitions
YoY Change
Other Investing Activities -$6.211M $32.34M -$175.2M
YoY Change -797.87% -13978.97% -1251357.14%
Cash From Investing Activities -$6.686M $34.06M -$175.8M
YoY Change -1759.06% -8657.29% 10387.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 413.0K 165.0K 880.0K
YoY Change 71.37% -99.83% -99.08%
NET CHANGE
Cash From Operating Activities -31.79M -29.64M 322.0K
Cash From Investing Activities -6.686M 34.06M -175.8M
Cash From Financing Activities 413.0K 165.0K 880.0K
Net Change In Cash -38.06M 4.586M -174.9M
YoY Change 29.94% -93.75% -2277.89%
FREE CASH FLOW
Cash From Operating Activities -$31.79M -$29.64M $322.0K
Capital Expenditures $475.0K -$1.720M $602.0K
Free Cash Flow -$32.26M -$27.92M -$280.0K
YoY Change 5.8% 35.7% -99.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 rptx Income Tax Examination Year Subject To Examination
IncomeTaxExaminationYearSubjectToExamination
2017 2018 2019 2020 2021 2022
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A8
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001808158
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2021 us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
CY2020Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.16496
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-39335
CY2022 dei Entity Registrant Name
EntityRegistrantName
Repare Therapeutics Inc.
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
7210 Frederick-Banting
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
St-Laurent
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
QC
CY2022 dei Entity Address Country
EntityAddressCountry
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
H4S 2A1
CY2022 dei City Area Code
CityAreaCode
857
CY2022 dei Local Phone Number
LocalPhoneNumber
412-7018
CY2022 dei Security12b Title
Security12bTitle
Common Shares, no par value
CY2022 dei Trading Symbol
TradingSymbol
RPTX
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1240000
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
454878023
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42077896
CY2022 dei Auditor Firm
AuditorFirmId
1263
CY2022 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2022 dei Auditor Location
AuditorLocation
Montréal, Canada
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159521000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
334427000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
184420000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
7439000
CY2022Q4 rptx Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
1280000
CY2021Q4 rptx Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
2580000
CY2022Q4 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
1525000
CY2021Q4 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
0
CY2022Q4 us-gaap Other Receivables
OtherReceivables
1518000
CY2021Q4 us-gaap Other Receivables
OtherReceivables
654000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5715000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6314000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
353979000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
351414000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4228000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5604000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5371000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7491000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
497000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
586000
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
0
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
3620000
CY2022Q4 us-gaap Assets
Assets
364075000
CY2021Q4 us-gaap Assets
Assets
368715000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
461000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2302000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
21645000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
18622000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2171000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1721000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
53102000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11921000
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
523000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
78619000
CY2021 us-gaap Investment Income Net
InvestmentIncomeNet
259000
CY2022 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
43000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
35089000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3257000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5592000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2682000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
39613000
CY2022Q4 us-gaap Liabilities
Liabilities
84558000
CY2021Q4 us-gaap Liabilities
Liabilities
80294000
CY2022Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2021Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2021Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42036193
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42036193
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41850162
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41850162
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
482032000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
480699000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
37226000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
17988000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-428000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-239313000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-210266000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
279517000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
288421000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
364075000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
368715000
CY2022 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
131830000
CY2021 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
7600000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
119066000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
90047000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32560000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26213000
CY2022 us-gaap Operating Expenses
OperatingExpenses
151626000
CY2021 us-gaap Operating Expenses
OperatingExpenses
116260000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-19796000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-108660000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
308000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-144000
CY2022 us-gaap Investment Income Net
InvestmentIncomeNet
5631000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2233000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-113000
CY2021 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
41000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5896000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
74000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13900000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-108586000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15147000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1678000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-29047000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-106908000
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-428000
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-428000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29475000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-106908000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.83
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.83
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41922042
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41922042
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37818115
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37818115
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
286830000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
986000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12829000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
113000
CY2021 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-106908000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
288421000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
447000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19691000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-428000
CY2022 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-29047000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
279517000
CY2022 us-gaap Profit Loss
ProfitLoss
-29047000
CY2021 us-gaap Profit Loss
ProfitLoss
-106908000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
19691000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
12829000
CY2022 us-gaap Depreciation
Depreciation
1978000
CY2021 us-gaap Depreciation
Depreciation
1471000
CY2022 us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
2206000
CY2021 us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
1873000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-24000
CY2022 rptx Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
298000
CY2021 rptx Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
-12000
CY2022 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-3620000
CY2021 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
2208000
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-593000
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
32000
CY2022 rptx Increase Decrease In Research And Development Tax Credits Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable
-1287000
CY2021 rptx Increase Decrease In Research And Development Tax Credits Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable
556000
CY2022 rptx Increase Decrease In Collaboration Revenue Receivable
IncreaseDecreaseInCollaborationRevenueReceivable
1525000
CY2021 rptx Increase Decrease In Collaboration Revenue Receivable
IncreaseDecreaseInCollaborationRevenueReceivable
0
CY2022 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
1147000
CY2021 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-3554000
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-89000
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
298000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1348000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
152000
CY2022 rptx Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
3020000
CY2021 rptx Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
11166000
CY2022 rptx Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
615000
CY2021 rptx Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
98000
CY2022 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
717000
CY2021 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
505000
CY2022 rptx Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
-2146000
CY2021 rptx Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
-1118000
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
4250000
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6473000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
322000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-85796000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
602000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1690000
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2021 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
40000
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
81400000
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
7450000
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
256576000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
7476000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-175778000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1676000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
447000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
986000
CY2022 rptx Proceeds From Issuance Of Common Stock Under Two Thousand Twenty Employee Share Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan
433000
CY2021 rptx Proceeds From Issuance Of Common Stock Under Two Thousand Twenty Employee Share Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan
283000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
94288000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
880000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
95557000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-330000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-54000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-174906000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8031000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
334427000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
326396000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
159521000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
334427000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
1966000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
240000
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
10810000
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
25000
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1719000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
86000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4690000
CY2022 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2016-09-06
CY2020Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-6.062
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-239300000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, share-based compensation, right-of-use assets and lease liabilities and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. Our investment portfolio comprises money market funds, U.S. treasury bills and U.S. treasury notes. Our investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company maintains deposits in accredited financial institutions which exceed insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s exposure to foreign exchange risk is primarily related to fluctuations between the Canadian dollar and the U.S. dollar. There are balances in Canadian dollars which are subject to foreign currency fluctuations relating to the impact of translating to U.S. dollars for financial statement presentation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had no significant off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span></span>
CY2022 us-gaap Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk
ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
As of December 31, 2022 and 2021, the Company had no significant off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.
CY2021 us-gaap Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk
ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
As of December 31, 2022 and 2021, the Company had no significant off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.
CY2022 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0
CY2022Q4 rptx Fair Value Assets Transfers Between All Levels
FairValueAssetsTransfersBetweenAllLevels
0
CY2021Q4 rptx Fair Value Assets Transfers Between All Levels
FairValueAssetsTransfersBetweenAllLevels
0
CY2022Q4 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
400000
CY2021Q4 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
0
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
28
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
0
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
157900000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
0
CY2022 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0
CY2021 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0
CY2022 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
400000
CY2021 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9581000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8979000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5353000
CY2022Q4 rptx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
21645000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3375000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4228000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5604000
CY2022 us-gaap Depreciation
Depreciation
1978000
CY2021 us-gaap Depreciation
Depreciation
1471000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5616000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4867000
CY2022Q4 rptx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
15078000
CY2021Q4 rptx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
11272000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
680000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
387000
CY2022Q4 rptx Accrued Property And Equipment Purchases
AccruedPropertyAndEquipmentPurchases
0
CY2021Q4 rptx Accrued Property And Equipment Purchases
AccruedPropertyAndEquipmentPurchases
1719000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
271000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
377000
CY2021Q4 rptx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
18622000
CY2022 rptx Number Of Operating Leases
NumberOfOperatingLeases
4
CY2022 us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
false
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
2456000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
2101000
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
33000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
25000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
278000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
163000
CY2022 us-gaap Lease Cost
LeaseCost
2767000
CY2021 us-gaap Lease Cost
LeaseCost
2289000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
1948000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
1240000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
86000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4690000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y5M4D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y4M6D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.040
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.040
CY2022 rptx Implicit Interest Rate
ImplicitInterestRate
0
CY2021 rptx Implicit Interest Rate
ImplicitInterestRate
0
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2342000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2395000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
957000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5694000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
266000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5428000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each common share entitles the holder to one vote on all matters submitted to the shareholders for a vote.
CY2022 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.54
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
22.49
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5322591
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.76
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M24D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
55722000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3346567
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.41
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
148116
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.02
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
488140
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
22.15
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8032902
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.38
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
37250000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3592087
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.41
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y11M8D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
28538000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4440815
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
16.79
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y7M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
8712000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1700000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
8500000
CY2022 rptx Fair Value Of Vested Options
FairValueOfVestedOptions
20100000
CY2021 rptx Fair Value Of Vested Options
FairValueOfVestedOptions
7400000
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
148116
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.02
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
400000
CY2022 rptx Additional Paid In Capital Share Based Payment Arrangement Exercised Options Credited To Common Shares
AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares
300000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19691000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12829000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19691000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12829000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
42900000
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2021Q1 rptx Defined Contribution Plan Employer Non Matching Contribution Percent
DefinedContributionPlanEmployerNonMatchingContributionPercent
0.03
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
800000
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
500000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-17550000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-110433000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
3650000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
1847000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13900000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-108586000
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
11527000
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
530000
CY2022 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
3620000
CY2021 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-2208000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15147000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1678000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13900000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-108586000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.265
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.265
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3684000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-28775000
CY2022 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
4899000
CY2021 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
4093000
CY2022 rptx Income Tax Rate Reconciliation Nondeductible Expense Accounting Charges
IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges
679000
CY2021 rptx Income Tax Rate Reconciliation Nondeductible Expense Accounting Charges
IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges
1078000
CY2022 rptx Income Tax Reconciliation Capital Gain Income Equity Compensation
IncomeTaxReconciliationCapitalGainIncomeEquityCompensation
-13956000
CY2021 rptx Income Tax Reconciliation Capital Gain Income Equity Compensation
IncomeTaxReconciliationCapitalGainIncomeEquityCompensation
0
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
3492000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
2220000
CY2022 rptx Income Tax Reconciliation State Taxes
IncomeTaxReconciliationStateTaxes
-777000
CY2021 rptx Income Tax Reconciliation State Taxes
IncomeTaxReconciliationStateTaxes
-37000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-142000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
644000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
34434000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
27285000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15147000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1678000
CY2022 rptx Income Tax Losses
IncomeTaxLosses
158500000
CY2022 rptx Income Tax Losses Expire One
IncomeTaxLossesExpireOne
45279000
CY2022 rptx Income Tax Losses Expire Two
IncomeTaxLossesExpireTwo
93834000
CY2022 rptx Income Tax Losses Expire Three
IncomeTaxLossesExpireThree
0
CY2022 rptx Income Tax Losses Expire Four
IncomeTaxLossesExpireFour
11394000
CY2022 rptx Income Tax Losses Expire Five
IncomeTaxLossesExpireFive
7111000
CY2022 rptx Income Tax Losses Expire Six
IncomeTaxLossesExpireSix
883000
CY2022 rptx Income Tax Losses
IncomeTaxLosses
158501000
CY2022 rptx Scientific Research And Experimental Development Expenditures
ScientificResearchAndExperimentalDevelopmentExpenditures
54600000
CY2022Q4 rptx Investment Tax Credits
InvestmentTaxCredits
9000000.0
CY2022Q4 rptx Investment Tax Credits Expire One
InvestmentTaxCreditsExpireOne
2392000
CY2022Q4 rptx Investment Tax Credits Expire Two
InvestmentTaxCreditsExpireTwo
2253000
CY2022Q4 rptx Investment Tax Credits Expire Three
InvestmentTaxCreditsExpireThree
1702000
CY2022Q4 rptx Investment Tax Credits Expire Four
InvestmentTaxCreditsExpireFour
1362000
CY2022Q4 rptx Investment Tax Credits Expire Five
InvestmentTaxCreditsExpireFive
776000
CY2022Q4 rptx Investment Tax Credits Expire Six
InvestmentTaxCreditsExpireSix
455000
CY2022Q4 rptx Investment Tax Credits Expire Seven
InvestmentTaxCreditsExpireSeven
24000
CY2022Q4 rptx Investment Tax Credits
InvestmentTaxCredits
8964000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
42003000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
30093000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
14468000
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
10656000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2369000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3538000
CY2022Q4 rptx Deferred Tax Assets Net Federal Investment Tax Credits
DeferredTaxAssetsNetFederalInvestmentTaxCredits
6589000
CY2021Q4 rptx Deferred Tax Assets Net Federal Investment Tax Credits
DeferredTaxAssetsNetFederalInvestmentTaxCredits
4805000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
0
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1775000
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
376000
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
0
CY2022Q4 rptx Deferred Tax Assets Operating Lease Right Of Use Assets
DeferredTaxAssetsOperatingLeaseRightOfUseAssets
1429000
CY2021Q4 rptx Deferred Tax Assets Operating Lease Right Of Use Assets
DeferredTaxAssetsOperatingLeaseRightOfUseAssets
1995000
CY2022Q4 rptx Deferred Tax Liabilities Operating Lease Liability
DeferredTaxLiabilitiesOperatingLeaseLiability
1445000
CY2021Q4 rptx Deferred Tax Liabilities Operating Lease Liability
DeferredTaxLiabilitiesOperatingLeaseLiability
1950000
CY2022Q4 rptx Deferred Tax Liabilities Accrued Expense And Other Liabilities
DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities
785000
CY2021Q4 rptx Deferred Tax Liabilities Accrued Expense And Other Liabilities
DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities
760000
CY2022Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
14783000
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
13656000
CY2022Q4 rptx Deferred Tax Assets Share Based Compensation Cost
DeferredTaxAssetsShareBasedCompensationCost
2492000
CY2021Q4 rptx Deferred Tax Assets Share Based Compensation Cost
DeferredTaxAssetsShareBasedCompensationCost
988000
CY2022Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
13911000
CY2021Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
0
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
97040000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
66226000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
97040000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
62606000
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
3620000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
97000000.0
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
62600000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-29047000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-106908000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41922042
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41922042
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37818115
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37818115
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.83
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.83
CY2022 rptx Increase Decrease In Research And Development Expenses
IncreaseDecreaseInResearchAndDevelopmentExpenses
1400000
CY2021 rptx Increase Decrease In Research And Development Expenses
IncreaseDecreaseInResearchAndDevelopmentExpenses
1100000
CY2022Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
3090000
CY2022Q4 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
3106000
CY2022Q4 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
32000
CY2022Q4 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
56000
CY2022Q4 us-gaap Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
32000
CY2022Q4 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
63000
CY2022Q4 us-gaap Contractual Obligation
ContractualObligation
6379000
CY2022Q4 us-gaap Foreign Currency Derivative Instruments Not Designated As Hedging Instruments At Fair Value Net
ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet
-4250000
CY2021Q4 us-gaap Foreign Currency Derivative Instruments Not Designated As Hedging Instruments At Fair Value Net
ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet
-756000
CY2022 rptx Percentage Of Depreciation Usd Against Canadian Dollar
PercentageOfDepreciationUSDAgainstCanadianDollar
0.10
CY2022 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
300000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4228000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5604000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5371000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7491000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-23-005113-index-headers.html Edgar Link pending
0000950170-23-005113-index.html Edgar Link pending
0000950170-23-005113.txt Edgar Link pending
0000950170-23-005113-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img192321128_0.jpg Edgar Link pending
img192321128_1.jpg Edgar Link pending
img192321128_10.jpg Edgar Link pending
img192321128_11.jpg Edgar Link pending
img192321128_12.jpg Edgar Link pending
img192321128_13.jpg Edgar Link pending
img192321128_14.jpg Edgar Link pending
img192321128_15.jpg Edgar Link pending
img192321128_16.jpg Edgar Link pending
img192321128_17.jpg Edgar Link pending
img192321128_18.jpg Edgar Link pending
img192321128_19.jpg Edgar Link pending
img192321128_2.jpg Edgar Link pending
img192321128_20.jpg Edgar Link pending
img192321128_21.jpg Edgar Link pending
img192321128_22.jpg Edgar Link pending
img192321128_3.jpg Edgar Link pending
img192321128_4.jpg Edgar Link pending
img192321128_5.jpg Edgar Link pending
img192321128_6.jpg Edgar Link pending
img192321128_7.jpg Edgar Link pending
img192321128_8.jpg Edgar Link pending
img192321128_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rptx-20221231.htm Edgar Link pending
rptx-20221231.xsd Edgar Link pending
rptx-ex10_31.htm Edgar Link pending
rptx-ex10_32.htm Edgar Link pending
rptx-ex10_33.htm Edgar Link pending
rptx-ex23_1.htm Edgar Link pending
rptx-ex31_1.htm Edgar Link pending
rptx-ex31_2.htm Edgar Link pending
rptx-ex32_1.htm Edgar Link pending
Show.js Edgar Link pending
rptx-20221231_cal.xml Edgar Link unprocessable
rptx-20221231_def.xml Edgar Link unprocessable
rptx-20221231_pre.xml Edgar Link unprocessable
rptx-20221231_lab.xml Edgar Link unprocessable
rptx-20221231_htm.xml Edgar Link completed